Modus Therapeutics Holding AB (MODTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) has a cash flow conversion efficiency ratio of -0.552x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.00 Million ≈ $-538.40K USD) by net assets (Skr9.07 Million ≈ $976.18K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MODTX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Modus Therapeutics Holding AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Modus Therapeutics Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Modus Therapeutics Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Modus Therapeutics Holding AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Equity Story Group Ltd
AU:EQS
|
0.833x |
|
Imunon Inc
NASDAQ:IMNN
|
-1.186x |
|
Iron Road Ltd
AU:IRD
|
-0.021x |
|
Nrgene Technologies Ltd
TA:NRGN
|
0.392x |
|
Orient Press Limited
NSE:ORIENTLTD
|
0.114x |
|
Dnonce Tech Bhd
KLSE:7114
|
0.031x |
|
Patkol Public Company Limited
BK:PK
|
-0.022x |
|
Dynasty Gold Corp
V:DYG
|
0.010x |
Annual Cash Flow Conversion Efficiency for Modus Therapeutics Holding AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Modus Therapeutics Holding AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Modus Therapeutics Holding AB (MODTX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr9.07 Million ≈ $976.18K |
Skr-18.07 Million ≈ $-1.95 Million |
-1.993x | +71.00% |
| 2024-12-31 | Skr2.14 Million ≈ $229.98K |
Skr-14.68 Million ≈ $-1.58 Million |
-6.870x | -628.09% |
| 2023-12-31 | Skr17.68 Million ≈ $1.90 Million |
Skr-16.68 Million ≈ $-1.80 Million |
-0.944x | -111.23% |
| 2022-12-31 | Skr-2.58 Million ≈ $-278.19K |
Skr-21.72 Million ≈ $-2.34 Million |
8.404x | +922.46% |
| 2021-12-31 | Skr15.73 Million ≈ $1.69 Million |
Skr-16.08 Million ≈ $-1.73 Million |
-1.022x | +1.16% |
| 2020-12-31 | Skr7.00 Million ≈ $752.77K |
Skr-7.23 Million ≈ $-778.17K |
-1.034x | -106.33% |
| 2019-12-31 | Skr-2.69 Million ≈ $-289.06K |
Skr-43.90 Million ≈ $-4.72 Million |
16.343x | +1075.08% |
| 2018-12-31 | Skr23.90 Million ≈ $2.57 Million |
Skr-40.06 Million ≈ $-4.31 Million |
-1.676x | -- |
About Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more